Compare Orion Office REIT Inc (ONL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs GeneDx Holdings Corp — how do they compare? Orion Office REIT Inc trades at $2.55 (market cap $151.74M), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is far larger — about 16.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ONL | WGS | |
|---|---|---|
Market Cap | $151.74M | $2.56B |
Sector | Real Estate | Technology |
52-Week High | $3.00 | $167.51 |
52-Week Low | $1.93 | $34.51 |
Enterprise Value | $568.67M | $2.60B |
Dividend Yield | 3.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Orion Office REIT (ONL) trades at $2.66, down 1.85% on the day, with a bearish technical outlook and mixed fundamentals. The company reported a Q2 2026 earnings beat but continues to post significant net losses, with a negative net income margin of -65.66% in 2025. Despite a low price-to-book ratio of 0.24, indicating potential undervaluation, declining revenues and negative profitability metrics highlight ongoing challenges in its office property portfolio.
The outlook remains cautious due to persistent operational losses and high debt levels, though analyst sentiment is split evenly between Buy and Hold. Key risks include further revenue erosion and interest expense pressures, while potential catalysts hinge on successful portfolio repositioning and stabilized office demand as highlighted in recent earnings calls.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
